AI Engines For more Details: Perplexity Kagi Labs You
Lowering Blood Pressure: Benzthiazide works by increasing the elimination of sodium and water from the body through urine, which helps reduce blood volume and subsequently lowers blood pressure. By reducing blood pressure, benzthiazide helps decrease the risk of complications associated with hypertension, such as heart attack, stroke, and kidney damage.
Edema: Benzthiazide is effective in reducing edema by promoting the elimination of excess fluid and salt from the body. It is commonly used to alleviate edema associated with conditions such as congestive heart failure, liver cirrhosis, and kidney disorders. By reducing fluid accumulation in the body, benzthiazide helps relieve symptoms such as swelling, shortness of breath, and fatigue.
Heart Failure: In patients with congestive heart failure, benzthiazide can help alleviate symptoms of fluid overload by reducing fluid retention and relieving pressure on the heart. This can improve overall cardiac function and alleviate symptoms such as shortness of breath, fatigue, and swelling in the extremities.
Kidney Disorders: Thiazide diuretics like benzthiazide can be beneficial in managing certain kidney disorders, such as nephrotic syndrome and chronic kidney disease, by promoting fluid and salt excretion and helping to regulate blood pressure. By reducing fluid overload and blood pressure, benzthiazide may slow the progression of kidney damage in some cases.
Calcium Regulation: Thiazide diuretics like benzthiazide have been found to increase the excretion of calcium in the urine, which can help reduce the risk of kidney stones in patients prone to calcium oxalate stone formation.
Metabolic Effects: Thiazide diuretics may have metabolic effects such as increasing blood glucose levels and altering lipid profiles. These effects should be monitored in patients with diabetes or lipid disorders.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.5 | 0.3 | 10.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2 | 1.4 | 0.43 |
| Allergies | 3.4 | 1.3 | 1.62 |
| Allergy to milk products | 0.6 | 1 | -0.67 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 3.2 | 3.6 | -0.13 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0 | 0 |
| Ankylosing spondylitis | 2.4 | 0.9 | 1.67 |
| Anorexia Nervosa | 1.1 | 2.1 | -0.91 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.3 | 0.33 |
| Asthma | 4.6 | 2.2 | 1.09 |
| Atherosclerosis | 1.2 | 1 | 0.2 |
| Atrial fibrillation | 2.9 | 1.4 | 1.07 |
| Autism | 4.8 | 5 | -0.04 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1.3 | 1.1 | 0.18 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.9 | 1.2 | -0.33 |
| Carcinoma | 3.5 | 2.3 | 0.52 |
| Celiac Disease | 1.3 | 3.2 | -1.46 |
| Cerebral Palsy | 1.2 | 1 | 0.2 |
| Chronic Fatigue Syndrome | 2.8 | 3.9 | -0.39 |
| Chronic Kidney Disease | 2.2 | 1.5 | 0.47 |
| Chronic Lyme | 0 | 0.8 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.7 | -0.31 |
| Chronic Urticaria (Hives) | 0.6 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 2.7 | 1.4 | 0.93 |
| Colorectal Cancer | 3.7 | 1.7 | 1.18 |
| Constipation | 0.6 | 0.7 | -0.17 |
| Coronary artery disease | 0.9 | 1.6 | -0.78 |
| COVID-19 | 6 | 5.7 | 0.05 |
| Crohn's Disease | 4.4 | 3.6 | 0.22 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.7 | -1.7 | |
| deep vein thrombosis | 0.1 | 1.1 | -10 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 6.5 | 6.1 | 0.07 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.9 | 1.5 | -0.67 |
| Endometriosis | 2 | 1.4 | 0.43 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 1.6 | 1.6 | 0 |
| erectile dysfunction | 0.6 | 0.3 | 1 |
| Fibromyalgia | 2.8 | 0.6 | 3.67 |
| Functional constipation / chronic idiopathic constipation | 2.6 | 1.7 | 0.53 |
| gallstone disease (gsd) | 1.4 | 1.1 | 0.27 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 1.1 | -0.57 |
| Generalized anxiety disorder | 1.3 | 1.2 | 0.08 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.8 | 0 | 0 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.4 | 0.3 | 0.33 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 2.4 | 1.2 | 1 |
| Heart Failure | 1.2 | 1 | 0.2 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0 | 0 |
| hyperglycemia | 1.6 | 1.2 | 0.33 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.1 | 3.3 | -0.06 |
| Hypothyroidism | 0 | 0.7 | 0 |
| Hypoxia | 1.6 | 0.3 | 4.33 |
| IgA nephropathy (IgAN) | 1.6 | 2 | -0.25 |
| Inflammatory Bowel Disease | 4.1 | 5.4 | -0.32 |
| Insomnia | 2 | 2.1 | -0.05 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 1.1 | 0.3 | 2.67 |
| Irritable Bowel Syndrome | 3.5 | 3 | 0.17 |
| ischemic stroke | 2.1 | 1.1 | 0.91 |
| Liver Cirrhosis | 5.6 | 3.5 | 0.6 |
| Long COVID | 3.8 | 5.8 | -0.53 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | 0.7 | -1.33 |
| Mast Cell Issues / mastitis | 0.4 | 0.3 | 0.33 |
| ME/CFS with IBS | 0.5 | 1.4 | -1.8 |
| ME/CFS without IBS | 1.1 | 1.5 | -0.36 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 0.6 | 1.17 |
| Metabolic Syndrome | 4.9 | 5.2 | -0.06 |
| Mood Disorders | 6.4 | 4.8 | 0.33 |
| multiple chemical sensitivity [MCS] | 1 | 0.1 | 9 |
| Multiple Sclerosis | 4.4 | 2.5 | 0.76 |
| Multiple system atrophy (MSA) | 0.3 | 0.4 | -0.33 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 0.7 | 1.3 | -0.86 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.3 | 3.2 | 0.03 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 6.4 | 6.1 | 0.05 |
| obsessive-compulsive disorder | 2.3 | 2.2 | 0.05 |
| Osteoarthritis | 0.8 | 0.9 | -0.13 |
| Osteoporosis | 1.4 | 1.3 | 0.08 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 5 | 3.6 | 0.39 |
| Polycystic ovary syndrome | 3.2 | 2.1 | 0.52 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 0.9 | 0.33 |
| Primary sclerosing cholangitis | 2.1 | 1.1 | 0.91 |
| Psoriasis | 1.8 | 1.3 | 0.38 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.9 | 3.1 | 0.58 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 4.8 | 2.3 | 1.09 |
| scoliosis | 0.4 | -0.4 | |
| Sjögren syndrome | 2 | 2.4 | -0.2 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.4 | 2 |
| Stress / posttraumatic stress disorder | 2.4 | 2.4 | 0 |
| Systemic Lupus Erythematosus | 2.6 | 1.5 | 0.73 |
| Tic Disorder | 0.6 | 1.2 | -1 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 1.5 | 2.9 | -0.93 |
| Type 2 Diabetes | 4.9 | 4 | 0.23 |
| Ulcerative colitis | 2.8 | 2.7 | 0.04 |
| Unhealthy Ageing | 2.6 | 1.6 | 0.63 |
| Vitiligo | 1.6 | 0.7 | 1.29 |
